Although these findings were suggestive of unique clinicopathologic patterns and signal of prognostic implications, the potential role of acquired MYC alterations in therapeutic resistance including immune evasion in HNSCC could not be interrogated. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.